Bibliography
- Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov Today 2006;11(7-8):277-9
- Drews J. Drug discovery: a historical perspective. Science 2000;287(5460):1960-4
- Mayr LM, Fuerst P. The future of high-throughput screening. J Biomol Screen 2008;13(6):443-8
- Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8(3):203-12
- Entzeroth M. Emerging trends in high-throughput screening. Curr Opin Pharmacol 2003;3(5):522-9
- Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches. Drug Discov Today 2006;11(15-16):741-8
- Mahapatra A. Screening for success. ACS Chem Biol 2008;3(8):449-50
- Harper G, Pickett SD, Green DV. Design of a compound screening collection for use in high throughput screening. Comb Chem High Throughput Screen 2004;7(1):63-70
- Lipkin MJ, Stevens AP, Livingstone DJ, Harris CJ. How large does a compound screening collection need to be? Comb Chem High Throughput Screen 2008;11(6):482-93
- Kirchmair J, Distinto S, Schuster D, et al. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr Med Chem 2008;15(20):2040-53
- Cavasotto CN, Orry AJ. Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem 2007;7(10):1006-14
- Kontoyianni M, Madhav P, Suchanek E, Seibel W. Theoretical and practical considerations in virtual screening: a beaten field? Curr Med Chem 2008;15(2):107-16
- Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002;1(11):882-94
- Davies JW, Glick M, Jenkins JL. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr Opin Chem Biol 2006;10(4):343-51
- Guido RV, Oliva G, Andricopulo AD. Virtual screening and its integration with modern drug design technologies. Curr Med Chem 2008;15(1):37-46
- Mestres J. Virtual screening: a real screening complement to high-throughput screening. Biochem Soc Trans 2002;30(4):797-9
- Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006;11(13-14):580-94
- Fox S, Farr-Jones S, Sopchak L, et al. In: Moraga CA, editor, High throughput screening: new users, more cell-based assays, and a host of new tools. High tech business decisions; 2005
- Fox S, Farr-Jones S, Sopchak L, et al. High-throughput screening: update on practices and success. J Biomol Screen 2006;11(7):864-9
- International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431(7011):931-45
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6
- Lundqvist T. The devil is still in the details–driving early drug discovery forward with biophysical experimental methods. Curr Opin Drug Discov Devel 2005;8(4):513-9
- Malo N, Hanley JA, Cerquozzi S, et al. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006;24(2):167-75
- Nell PG, Mundt SM. High throughput-screening in drug discovery. Weinheim: WILEY-VCH Verlag GmBH & Co. KGaA, 2006
- Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005;10(23-24):1675-82
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26
- Evers A, Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 2005;48(4):1088-97
- Evers A, Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem 2004;47(22):5381-92
- Cavasotto CN, Orry AJ, Murgolo NJ, et al. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 2008;51(3):581-8
- Richardson CM, Nunns CL, Williamson DS, et al. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. Bioorg Med Chem Lett 2007;17(14):3880-5
- Sandberg EM, Ma X, He K, et al. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem 2005;48(7):2526-33
- Forino M, Jung D, Easton JB, et al. Virtual docking approaches to protein kinase B inhibition. J Med Chem 2005;48(7):2278-81
- Cavasotto CN, Ortiz MA, Abagyan RA, Piedrafita FJ. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Bioorg Med Chem Lett 2006;16(7):1969-74
- Shao D, Berrodin TJ, Manas E, et al. Identification of novel estrogen receptor alpha antagonists. J Steroid Biochem Mol Biol 2004;88(4-5):351-60
- Thurmond RL, Sun S, Sehon CA, et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J Pharmacol Exp Ther 2004;308(1):268-76
- Murray CW, Callaghan O, Chessari G, et al. Application of fragment screening by X-ray crystallography to beta-secretase. J Med Chem 2007;50(6):1116-23
- Fattorusso R, Jung D, Crowell KJ, et al. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. J Med Chem 2005;48(5):1649-56
- Stoermer MJ. Current status of virtual screening as analysed by target class. Med Chem 2006;2(1):89-112
- Inglese J, Shamu CE, Guy RK. Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol 2007;3(8):438-41
- Inglese J, Johnson RL, Simeonov A, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 2007;3(8):466-79
- Shelat AA, Guy RK. Scaffold composition and biological relevance of screening libraries. Nat Chem Biol 2007;3(8):442-6
- Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67-73
- Gagarin A, Makarenkov V, Zentilli P. Using clustering techniques to improve hit selection in high-throughput screening. J Biomol Screen 2006;11(8):903-14
- Brideau C, Gunter B, Pikounis B, Liaw A. Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 2003;8(6):634-47
- Yan SF, King FJ, He Y, et al. Learning from the data: mining of large high-throughput screening databases. J Chem Inf Model 2006;46(6):2381-95
- Harper G, Pickett SD. Methods for mining HTS data. Drug Discov Today 2006;11(15-16):694-9
- Costanzi S, Tikhonova IG, Harden TK, Jacobson KA. Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des 2008 http://dx.doi.org/10.1007/s10822-008-9218-3
- Omagari K, Mitomo D, Kubota S, et al. A method to enhance the hit ration by a combination of structure-based drug screening and ligand based drug screening. Adv Appl Bioinform Chem 2008;I:19-28
- Scapin G. Structural biology and drug discovery. Curr Pharm Des 2006;12(17):2087-97
- Rester U. From virtuality to reality – Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Dev 2008;11(4):559-68
- Fischer PM. Computational chemistry approaches to drug discovery in signal transduction. Biotechnol J 2008;3(4):452-70
- Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303(5665):1813-8
- Koppen H. Virtual screening – what does it give us? Curr Opin Drug Discov Devel 2009;12(3):397-407
- Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 2006;49(20):5851-5
- McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11(5):494-502
- Zoete V, Grosdidier A, Michielin O. Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 2009;13(2):238-48
- Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3(11):935-49
- Villoutreix BO, Renault N, Lagorce D, et al. Free resources to assist structure-based virtual ligand screening experiments. Curr Protein Pept Sci 2007;8(4):381-411
- Cavasotto CN, Phatak SS. Homology modelling in drug discovery: current trends and applications. Drug Discov Today 2009;14(13-14):676-83
- Kairys V, Fernandes MX, Gilson MK. Screening drug-like compounds by docking to homology models: a systematic study. J Chem Inf Model 2006;46(1):365-79
- Rester U. Dock around the clock-current status of small molecule docking and scoring. QSAR Comb Sci 2006;25(7):605-15
- Bacilieri M, Moro S. Ligand-based drug design methodologies in drug discovery process: an overview. Curr Drug Discov Technol 2006;3(3):155-65
- Guha R. On the interpretation and interpretability of quantitative structure-activity relationship models. J Comput Aided Mol Des 2008;22(12):857-71
- Polanski J. Receptor dependent multidimensional QSAR for modeling drug – receptor interactions. Curr Med Chem 2009 [Epub ahead of reprint]
- Schnecke V, Bostrom J. Computational chemistry-driven decision making in lead generation. Drug Discov Today 2006;11(1-2):43-50
- Chen J, Lai L. Pocket v.2: further developments on receptor-based pharmacophore modeling. J Chem Inf Model 2006;46(6):2684-91
- Sun H. Pharmacophore-based virtual screening. Curr Med Chem 2008;15(10):1018-24
- Muthas D, Sabnis YA, Lundborg M, Karlen A. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. J Mol Graph Model 2008;26(8):1237-51
- Barillari C, Marcou G, Rognan D. Hot-spots-guided receptor-based pharmacophores (HS-Pharm): a knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J Chem Inf Model 2008;48(7):1396-410
- Joseph-McCarthy D, Baber JC, Feyfant E, et al. Lead optimization via high-throughput molecular docking. Curr Opin Drug Discov Devel 2007;10(3):264-74
- Diaz P, Phatak SS, Xu J, et al. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. J Med Chem 2009;52(2):433-44
- Diaz P, Phatak SS, Xu J, et al. 2,3-dihydro-1-benzofuran derivatives as a novel series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem 2009. In press http://dx.doi.org/10.1002/cmdc.200900226
- Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261(3):470-89
- Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998;19:1639-62
- Butler KT, Luque FJ, Barril X. Toward accurate relative energy predictions of the bioactive conformation of drugs. J Comput Chem 2009;30(4):601-10
- Barril X, Fradera X. Incorporating protein flexibility into docking and structure-based drug design. Expert Opin Drug Discov 2006;1:335-49
- Cavasotto CN, Singh N. Docking and high throughput docking: successes and the challenge of protein flexibility. Curr Comput Aided Drug Design 2008;4(3):221-34
- Corbeil CR, Moitessier N. Docking ligands into flexible and solvated macromolecules. 3. Impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs. J Chem Inf Model 2009;49(4):997-1009
- Jain AN. Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation. J Comput Aided Mol Des 2009;23(6):355-74
- B-Rao C, Subramanian J, Sharma SD. Managing protein flexibility in docking and its applications. Drug Discov Today 2009;14(7-8):394-400
- Shoichet BK. Virtual screening of chemical libraries. Nature 2004;432(7019):862-5
- Tirado-Rives J, Jorgensen WL. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J Med Chem 2006;49(20):5880-4
- Mobley DL, Dill KA, Chodera JD. Treating entropy and conformational changes in implicit solvent simulations of small molecules. J Phys Chem B 2008;112(3):938-46
- Warren GL, Andrews CW, Capelli AM, et al. A critical assessment of docking programs and scoring functions. J Med Chem 2006;49(20):5912-31
- Duca JS, Madison VS, Voigt JH. Cross-docking of inhibitors into CDK2 structures. 1. J Chem Inf Model 2008;48(3):659-68
- Jain AN. Scoring functions for protein-ligand docking. Curr Protein Pept Sci 2006;7(5):407-20
- Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol 2004;337(1):209-25
- Ghosh S, Nie A, An J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol 2006;10(3):194-202
- Yasgar A, Shinn P, Jadhav A, et al. Compound management for quantitative high-throughput screening. JALA Charlottesv Va 2008;13(2):79-89
- Briggs MW. Available from: http://www.highresbio.com/pdfs/Briggs_ALA2008.pdf [Cited]
- Schnur DM. Recent trends in library design: ‘rational design’ revisited. Curr Opin Drug Discov Devel 2008;11(3):375-80
- Edwards BS, Bologa C, Young SM, et al. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol 2005;68(5):1301-10
- Xu X, Kasembeli MM, Jiang X, et al. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 2009;4(3):e4783
- Jennings A, Tennant M. Discovery strategies in a pharmaceutical setting: the application of computational techniques. Expert Opinion Drug Discov 2006;1(7):709-21
- Olah MM, Bologa CG, Oprea TI. Strategies for compound selection. Curr Drug Discov Technol 2004;1(3):211-20
- Sun H. A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J Chem Inf Comput Sci 2004;44(2):748-57
- Orry AJ, Abagyan RA, Cavasotto CN. Structure-based development of target-specific compound libraries. Drug Discov Today 2006;11(5-6):261-6
- Lumley JA. Compound selection and filtering in library design. QSAR Comb Sci 2005;24(9):1066-75
- Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003;2(5):369-78
- Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005;4(8):649-63
- Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 2009;5(5):358-64
- Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6(3):211-9
- Villar HO, Hansen MR. Computational techniques in fragment based drug discovery. Curr Top Med Chem 2007;7(15):1509-13
- Claus BL, Johnson SR. Grid computing in large pharmaceutical molecular modeling. Drug Discov Today 2008;13(13-14):578-83
- Waller CL, Shah A, Nolte M. Strategies to support drug discovery through integration of systems and data. Drug Discov Today 2007;12(15-16):634-9
- Available from: http://accelrys.com/products/scitegic/
- Available from: www.chemapps.com
- Available from: http://www.knime.org
- Available from: www.inforsense.com
- Available from: http://taverna.sourceforge.net
- Waszkowycz B. Towards improving compound selection in structure-based virtual screening. Drug Discov Today 2008;13(5-6):219-26
- Paiva AM, Vanderwall DE, Blanchard JS, et al. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim Biophys Acta 2001;1545(1-2):67-77
- Doman TN, McGovern SL, Witherbee BJ, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 2002;45(11):2213-21
- Betzi S, Restouin A, Opi S, et al. Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein. Proc Natl Acad Sci USA 2007;104(49):19256-61
- Polgar T, Baki A, Szendrei GI, Keseru GM. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. J Med Chem 2005;48(25):7946-59
- Babaoglu K, Simeonov A, Irwin JJ, et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem 2008;51(8):2502-11
- Collins FS, Gray GM, Bucher JR. Toxicology. Transforming environmental health protection. Science 2008;319(5865):906-7
- Glaser V. High throughput screening. 2009; Available from: http://www.bio-itworld.com/uploadedFiles/Bio-IT_World/Bio-IT_Issues/2009/Jan-Feb/BIW_20090101B_Jan_2009%5B1%5D.pdf [Cited]